ESR1 and carcinoma: Although the study did not address intratumor heterogeneity, it clearly showed that a subgroup of HER2+ carcinomas was composed of ER‐negative tumors, one subgroup of highly ER‐positive tumors, and two subgroups of tumors with more intermediate ER levels.